Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Naproxen Etemesil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 known ✓ | P35354 | 6/20 | 0.76 |
| ▸ | PTGS1 known ✓ | P23219 | 2/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.58 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | CDC42 | P60953 | 1/20 | 0.58 |
| ▸ | RAC1 | P63000 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Naproxen Etemesil SCHEMBL3047558 | 1.00 | PTGS2 (0.76) | PTGS2TDP1L3MBTL1AKR1C3AKR1C2 | |
| Naproxen Etemesil SCHEMBL29385581 | 1.00 | PTGS2 (0.76) | PTGS2TDP1L3MBTL1AKR1C3AKR1C2 | |
| Naproxen Etemesil SCHEMBL29379069 | 1.00 | PTGS2 (0.76) | PTGS2TDP1L3MBTL1AKR1C3AKR1C2 | |
| SCHEMBL18878937 | 0.91 | PTGS2 (0.74) | PTGS2TDP1L3MBTL1AKR1C3AKR1C2 | |
| SCHEMBL13063771 | 0.86 | PTGS2 (0.71) | PTGS2TDP1L3MBTL1AKR1C3AKR1C2 | |
| SCHEMBL13592731 | 0.85 | TDP1 (0.69) | PTGS2TDP1L3MBTL1AKR1C3AKR1C2 | |
| SCHEMBL21253785 | 0.84 | PTGS2 (0.65) | PTGS2TDP1L3MBTL1AKR1C3AKR1C2 | |
| SCHEMBL13484161 | 0.84 | PTGS2 (0.65) | PTGS2TDP1L3MBTL1AKR1C3AKR1C2 | |
| SCHEMBL13095613 | 0.84 | PTGS2 (0.65) | PTGS2TDP1L3MBTL1AKR1C3AKR1C2 | |
| SCHEMBL1395949 | 0.84 | PTGS2 (0.65) | PTGS2TDP1L3MBTL1AKR1C3AKR1C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100221337-A1 | METHOD OF TREATING ARTHRITIS, PAIN OR INFLAMMATION WITH NAPROXEN 2(METHANESULFONYL)ETHYL ESTER AND AN H2 RECEPTOR ANTAGONIST | LOGICAL THERAPEUTICS, INC. (US) | 2010-09-02 | — | — | US | disclosed |
| US-20100221336-A1 | METHOD OF TREATING ARTHRITIS, PAIN OR INFLAMMATION WITH NAPROXEN 2(METHANESULFONYL)ETHYL ESTER AND A PROTON PUMP INHIBITOR | LOGICAL THERAPEUTICS, INC. (US) | 2010-09-02 | — | — | US | disclosed |
| US-20100221337-A1 | METHOD OF TREATING ARTHRITIS, PAIN OR INFLAMMATION WITH NAPROXEN 2(METHANESULFONYL)ETHYL ESTER AND AN H2 RECEPTOR ANTAGONIST | LOGICAL THERAPEUTICS, INC. (US) | 2010-09-02 | — | — | US | disclosed |
| US-20100221334-A1 | COMPOSITIONS INCLUDING LEUKOTRIENE ANTAGONISTS AND NSAIDS AND METHODS OF USING THE SAME | LOGICAL THERAPEUTICS, INC. | 2010-09-02 | — | — | US | disclosed |
| US-20100221336-A1 | METHOD OF TREATING ARTHRITIS, PAIN OR INFLAMMATION WITH NAPROXEN 2(METHANESULFONYL)ETHYL ESTER AND A PROTON PUMP INHIBITOR | LOGICAL THERAPEUTICS, INC. (US) | 2010-09-02 | — | — | US | disclosed |
| US-20100221334-A1 | COMPOSITIONS INCLUDING LEUKOTRIENE ANTAGONISTS AND NSAIDS AND METHODS OF USING THE SAME | LOGICAL THERAPEUTICS, INC. | 2010-09-02 | — | — | US | disclosed |
| US-20100221334-A1 | COMPOSITIONS INCLUDING LEUKOTRIENE ANTAGONISTS AND NSAIDS AND METHODS OF USING THE SAME | LOGICAL THERAPEUTICS, INC. | 2010-09-02 | — | — | US | disclosed |
| US-RE41151-E1 | Protected forms of pharmacologically active agents and uses thereof | MEDINOX, INC. (US) | 2010-02-23 | — | — | US | disclosed |
| US-RE41151-E1 | Protected forms of pharmacologically active agents and uses thereof | MEDINOX, INC. (US) | 2010-02-23 | — | — | US | disclosed |
| WO-2009012425-A2 | COMPOSITIONS INCLUDING LEUKOTRIENE ANTAGONISTS AND NSAIDS AND METHODS OF USING THE SAME | LOGIGAL THERAPEUTICS, INC. (US) | 2009-01-22 | — | — | WO | disclosed |
| WO-2009012425-A2 | COMPOSITIONS INCLUDING LEUKOTRIENE ANTAGONISTS AND NSAIDS AND METHODS OF USING THE SAME | LOGIGAL THERAPEUTICS, INC. (US) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100221334-A1 | COMPOSITIONS INCLUDING LEUKOTRIENE ANTAGONISTS AND NSAIDS AND METHODS OF USING THE SAME | LTC4S, LTB4R2, CYSLTR2 | PTGS2 24/4885PTGS1 23/4885TDP1 4446/4885 |
| US-20100221336-A1 | METHOD OF TREATING ARTHRITIS, PAIN OR INFLAMMATION WITH NAPROXEN 2(METHANESULFONYL)ETHYL ESTER AND A PROTON PUMP INHIBITOR | PTGES2, PTGS2, PTGES | PTGS2 2/4885PTGS1 4/4885TDP1 3949/4885 |
| US-20100221337-A1 | METHOD OF TREATING ARTHRITIS, PAIN OR INFLAMMATION WITH NAPROXEN 2(METHANESULFONYL)ETHYL ESTER AND AN H2 RECEPTOR ANTAGONIST | HRH2, PTGER2, HCAR2 | PTGS2 5/4885PTGS1 12/4885TDP1 4762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.